Clinical Trial Update: A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing BL-M07D1 to T-DM1 as adjuvant therapy for HER2-positive breast cancer with residual invasive disease after neoadjuvant therap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BL-M07D1
• T-DM1 (ado-trastuzumab emtansine)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: RECRUITING